Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 16/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.82 |
| ▸ | FGFR2 | P21802 | 11/20 | 0.82 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.82 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.80 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.80 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.80 |
| ▸ | HAMP | P81172 | 3/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21808296 | 1.00 | ACVR1 (1.00) | ACVR1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL21892115 | 1.00 | ACVR1 (1.00) | ACVR1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL21808272 | 0.91 | ACVR1 (0.84) | ACVR1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL21808273 | 0.91 | ACVR1 (0.84) | ACVR1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL21808505 | 0.91 | ACVR1 (1.00) | ACVR1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL21808507 | 0.91 | ACVR1 (1.00) | ACVR1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL21891830 | 0.91 | ACVR1 (1.00) | ACVR1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL21846658 | 0.90 | ACVR1 (1.00) | ACVR1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL21891979 | 0.90 | ACVR1 (1.00) | ACVR1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL21808275 | 0.89 | ACVR1 (1.00) | ACVR1FGFR1FGFR2FGFR3BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | claimed |
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | claimed |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-09-07 | — | — | US | claimed |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-26 | — | — | US | claimed |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250034148-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023081212-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-01-20 | — | — | US | disclosed |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| WO-2020068729-A1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS | INCYTE CORPORATION (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | ACVR1 7/4885FGFR1 2/4885FGFR2 3/4885 |
| US-20250034148-A1 | METHODS OF USING ALK2 INHIBITORS | ETV6, ALK, MPL | ACVR1 18/4885FGFR1 82/4885FGFR2 36/4885 |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | ACVR1 7/4885FGFR1 2/4885FGFR2 3/4885 |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | ACVR1 7/4885FGFR1 2/4885FGFR2 3/4885 |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | ACVR1 7/4885FGFR1 2/4885FGFR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.